Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Updates on α-synuclein as a biomarker in Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, F. Hoffmann – La Roche Ltd, Basel, Switzerland, outlines the challenges of using α-synuclein as a biomarker in Parkinson’s disease. Although it is possible to measure α-synuclein in a post-mortem evaluation of a brain, there are currently no methods available to reliably measure it in patients in vivo. Additionally, there is also no reliable quantitative measure of α-synuclein aggregates in the CSF. Seed amplification assays have been successfully applied to detect misfolded α-synuclein in the CSF of Parkinson’s disease patients, but these assays are not quantitative yet. Hopefully, the markers under development will become quantitative and able to be implemented in clinical trials. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.